Characteristics of the 2 cohorts matched for propensity score analysis
| Characteristic . | ALLPh08 (N = 30) . | PONALFIL (N = 30) . | P . |
|---|---|---|---|
| Male | 16/30 (53%) | 17/30 (57%) | .795 |
| Age, median [minimum; maximum], y | 46 (19, 56) | 49 (19, 59) | .439 |
| ECOG score <2 | 27 (90%) | 27 (90%) | 1.0 |
| White blood cell count, ×109/L | 1.0 | ||
| <30 | 22 (73%) | 22 (73%) | |
| ≥30 | 8 (27%) | 8 (27%) | |
| CNS involvement | 2 (7%) | 1 (3%) | 1.0 |
| Cytogenetics | .602 | ||
| t (9;22) | 16 (53%) | 18 (60%) | |
| t (9;22) with additional chromosomal abnormalities | 14 (47%) | 12 (40%) | |
| Isoform | .278 | ||
| p190 | 14 (47%) | 20 (67%) | |
| p210 | 15 (50%) | 9 (30%) | |
| p230 | 1 (3%) | 1 (3%) |
| Characteristic . | ALLPh08 (N = 30) . | PONALFIL (N = 30) . | P . |
|---|---|---|---|
| Male | 16/30 (53%) | 17/30 (57%) | .795 |
| Age, median [minimum; maximum], y | 46 (19, 56) | 49 (19, 59) | .439 |
| ECOG score <2 | 27 (90%) | 27 (90%) | 1.0 |
| White blood cell count, ×109/L | 1.0 | ||
| <30 | 22 (73%) | 22 (73%) | |
| ≥30 | 8 (27%) | 8 (27%) | |
| CNS involvement | 2 (7%) | 1 (3%) | 1.0 |
| Cytogenetics | .602 | ||
| t (9;22) | 16 (53%) | 18 (60%) | |
| t (9;22) with additional chromosomal abnormalities | 14 (47%) | 12 (40%) | |
| Isoform | .278 | ||
| p190 | 14 (47%) | 20 (67%) | |
| p210 | 15 (50%) | 9 (30%) | |
| p230 | 1 (3%) | 1 (3%) |